期刊
MOLECULAR CANCER THERAPEUTICS
卷 5, 期 12, 页码 3232-3239出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-06-0444
关键词
-
类别
资金
- NCI NIH HHS [R01 CA78814] Funding Source: Medline
The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1, 9(11)-dien-28-oyllimidazole (CDDO-Im) is a multifunctional agent with potent anti-inflammatory, antiproliferative, cytoprotective, and apoptotic activities, whose molecular targets are unknown. Using both cell-free and cellular assays, we show that CDDO-Im is a direct inhibitor of I kappa B kinase (IKK) beta and that it thereby inhibits binding of nuclear factor-kappa B to DNA and subsequent transcriptional activation. Pretreatment of cells with CDDO-Im prevents I kappa B alpha phosphorylation and degradation in response to tumor necrosis factor alpha. The kinetics of this inhibition by CDDO- Im are rapid and occur within 15 min. A biotinylated analogue of CDDO-Im showed that CDDO-Im binds to the IKK signalsome. Furthermore, we show that Cys(179) on IKK is a target for CDDO-Im. This is the first report to show that this novel synthetic triterpenoid binds to and inhibits IKK directly.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据